CMS'(Centers for Medicare and Medicaid Services) lumbar artificial disc replacement decision prolongs pain for US industry
This article was originally published in Clinica
The US Centers for Medicare and Medicaid Services' (CMS) denial last week of national coverage for Synthes' lumbar artificial disc replacement, ProDisc-L, will likely have more impact on prospective private usage than for the ostensible CMS target patient group - the over 60s.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.